(Q46883877)

26 December 2017

title

Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme (English)

1 reference

26 December 2017

0 references

1 reference

Gloria B Roldán Urgoiti

series ordinal

1

1 reference

26 December 2017

Amitabh D Singh

series ordinal

2

1 reference

26 December 2017

Jacob C Easaw

series ordinal

3

1 reference

26 December 2017

publication date

2 March 2012

1 reference

26 December 2017

Journal of Neuro-Oncology

published in

1 reference

26 December 2017

volume

108

1 reference

26 December 2017

issue

1

1 reference

26 December 2017

page(s)

173-177

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s11060-012-0826-3

exact match

0 references

cites work

Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Canadian recommendations for the treatment of glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Response criteria for phase II studies of supratentorial malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0826-3

Population-based study of pseudoprogression after chemoradiotherapy in GBM.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22382781

12 December 2020

inferred from PubMed ID database lookup

Pseudoprogression following chemoradiotherapy for glioblastoma multiforme.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22382781

12 December 2020

inferred from PubMed ID database lookup

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22382781

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S11060-012-0826-3

1 reference

26 December 2017

release_ijroir66krg5bhjjfhlnkod5oi

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ijroir66krg5bhjjfhlnkod5oi

24 November 2022

mapped directly with Wikidata item

1 reference

26 December 2017